In the same manner of interconverting between non-GSCs and GSCs, Auffinger et al. [57] found that therapeutic doses of TMZ notably increased the expression of various glioma stem cell markers, such as CD15 and CD133, in vitro and in vivo. This evidence concerns the gene PROM1 and glioma.